Opaleye’s Steady Buying of Sol‑Gel Shares Signals Undervalued Growth Potential
Opaleye’s steady buying of Sol‑Gel Technologies shares signals confidence in its dermatology pipeline, suggesting potential upside amid volatile biotech markets.
5 minutes to read